IL71906A - Method for producing a baculovirus vector capable of producing a selected non-fused recombinant protein or capable of being utilized as a transfer vector;a recombinant baculovirus expression vector capable of expressing under the control of a baculovirus polyhedrin promoter a selected non-fused protein in a host insect cell;a recombinant transfer vector utilizing a baculovirus polyhedrin promoter and flanking sequences for introducing a selected gene into a baculovirus genome,or for insertion of a selected gene for a genetic manipulation of a baculovirus;and a method for the synthesis of a selected non-fused protein in a host insect cell using the expression vector - Google Patents

Method for producing a baculovirus vector capable of producing a selected non-fused recombinant protein or capable of being utilized as a transfer vector;a recombinant baculovirus expression vector capable of expressing under the control of a baculovirus polyhedrin promoter a selected non-fused protein in a host insect cell;a recombinant transfer vector utilizing a baculovirus polyhedrin promoter and flanking sequences for introducing a selected gene into a baculovirus genome,or for insertion of a selected gene for a genetic manipulation of a baculovirus;and a method for the synthesis of a selected non-fused protein in a host insect cell using the expression vector

Info

Publication number
IL71906A
IL71906A IL71906A IL7190684A IL71906A IL 71906 A IL71906 A IL 71906A IL 71906 A IL71906 A IL 71906A IL 7190684 A IL7190684 A IL 7190684A IL 71906 A IL71906 A IL 71906A
Authority
IL
Israel
Prior art keywords
baculovirus
recombinant
selected non
producing
vector
Prior art date
Application number
IL71906A
Other languages
English (en)
Other versions
IL71906A0 (en
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/498,858 external-priority patent/US4745051A/en
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Publication of IL71906A0 publication Critical patent/IL71906A0/xx
Publication of IL71906A publication Critical patent/IL71906A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
IL71906A 1983-05-27 1984-05-23 Method for producing a baculovirus vector capable of producing a selected non-fused recombinant protein or capable of being utilized as a transfer vector;a recombinant baculovirus expression vector capable of expressing under the control of a baculovirus polyhedrin promoter a selected non-fused protein in a host insect cell;a recombinant transfer vector utilizing a baculovirus polyhedrin promoter and flanking sequences for introducing a selected gene into a baculovirus genome,or for insertion of a selected gene for a genetic manipulation of a baculovirus;and a method for the synthesis of a selected non-fused protein in a host insect cell using the expression vector IL71906A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/498,858 US4745051A (en) 1983-05-27 1983-05-27 Method for producing a recombinant baculovirus expression vector
US60969784A 1984-05-16 1984-05-16

Publications (2)

Publication Number Publication Date
IL71906A0 IL71906A0 (en) 1984-09-30
IL71906A true IL71906A (en) 1992-08-18

Family

ID=27052974

Family Applications (1)

Application Number Title Priority Date Filing Date
IL71906A IL71906A (en) 1983-05-27 1984-05-23 Method for producing a baculovirus vector capable of producing a selected non-fused recombinant protein or capable of being utilized as a transfer vector;a recombinant baculovirus expression vector capable of expressing under the control of a baculovirus polyhedrin promoter a selected non-fused protein in a host insect cell;a recombinant transfer vector utilizing a baculovirus polyhedrin promoter and flanking sequences for introducing a selected gene into a baculovirus genome,or for insertion of a selected gene for a genetic manipulation of a baculovirus;and a method for the synthesis of a selected non-fused protein in a host insect cell using the expression vector

Country Status (17)

Country Link
EP (1) EP0127839B1 (de)
JP (2) JPH0779700B2 (de)
KR (1) KR910009203B1 (de)
AT (1) ATE78293T1 (de)
AU (1) AU581174B2 (de)
BR (1) BR8402666A (de)
CA (1) CA1222213A (de)
DE (1) DE3485810T2 (de)
DK (1) DK172401B1 (de)
ES (1) ES8507176A1 (de)
IE (1) IE58011B1 (de)
IL (1) IL71906A (de)
IN (1) IN160416B (de)
MX (1) MX164250B (de)
NO (1) NO173944C (de)
NZ (1) NZ208259A (de)
PH (1) PH25395A (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
JPS619288A (ja) * 1984-06-21 1986-01-16 Dai Ichi Seiyaku Co Ltd ペプチド類の製法
US5004687A (en) * 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
GB8521496D0 (en) * 1985-08-29 1985-10-02 Ciba Geigy Ag Repressible yeast promoters
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
IL80529A0 (en) * 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
EP0228036A3 (de) * 1985-12-18 1988-09-07 Microgenesys, Inc. Verfahren zur Herstellung von spezifischen Polypeptiden in virusinfizierten Insektzellen und daraus isolierte Polypeptide
EP0260090A3 (de) * 1986-09-08 1988-07-27 David H.L. Bishop Expression von Hepatitis B-Virusantigenen von rekombinanten Bakulovirusvektoren
US5071748A (en) * 1986-09-09 1991-12-10 Genetics Institute, Inc. Mixed baculovirus compositions and uses thereof
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
JPH02502876A (ja) * 1987-03-16 1990-09-13 アメリカン　バイオジェネティック　サイエンシズ　インク ワクチンと生物学的殺虫剤における組換えバクロウイルス閉塞体
US5041379A (en) * 1987-03-16 1991-08-20 American Biogenetic Science, Inc. Heliothis expression systems
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
AU2083788A (en) * 1987-06-30 1989-01-30 Upjohn Company, The Virus proteins having reduced o-linked glycosylation
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5372943A (en) * 1987-07-24 1994-12-13 Cetus Corporation Lipid microemulsions for culture media
AU2251488A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
AU2136788A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5876962A (en) * 1987-08-12 1999-03-02 Natural Environment Research Council Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
FR2631974B1 (fr) * 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
DE68912248T2 (de) * 1988-09-16 1994-05-26 Sandoz Ag Diuretischer Faktor.
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
US5145775A (en) * 1989-02-28 1992-09-08 Research Association For Biotechnology Of Agricultural Chemicals Polyhedrin gene and genetic engineering thereof
GB8910962D0 (en) * 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
EP0533469A1 (de) * 1991-09-18 1993-03-24 Hong Kong Tech Company Limited Expressionsvektor und diesen enthaltender Seidenwurmtransformant
IT1259042B (it) * 1992-01-27 1996-03-11 Mini Ricerca Scient Tecnolog Preparazione di vettori di espressione per la sintesi del polipeptide chiamato fattore osteogenetico op-1 in cellule eucariotiche di spodoptera frugiperda via infezione con baculovirus ricombinante
ES2048646B1 (es) * 1992-04-15 1994-10-01 Ercros Sa Procedimiento para la obtencion de la proteina vp2 del virus de la peste equina africana (ahsv)
AU1377395A (en) 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5952210A (en) * 1994-06-03 1999-09-14 G. D. Searle & Company Nucleic acids and expression vectors encoding human leukotiene C4 synthase
JP2640623B2 (ja) * 1994-06-10 1997-08-13 日本製粉株式会社 ターミナルデオキシヌクレオチジルトランスフェラーゼの製造方法
DE69505076T2 (de) * 1994-07-29 1999-02-25 Teijin Ltd., Osaka Trypsintyp-Enzyme, dafür kodierende Nukleinsäuresequenz und Verfahren zur Herstellung des Enzymes
JP2565668B2 (ja) * 1995-01-17 1996-12-18 第一製薬株式会社 ペプチド類の製造用ベクター
FR2732035B1 (fr) * 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU736334B2 (en) * 1997-03-27 2001-07-26 University Of British Columbia, The Insect expression vectors
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
EP1121437B1 (de) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
ES2386317T3 (es) 2000-01-10 2012-08-17 Novartis Vaccines And Diagnostics, Inc. Genes expresados diferencialmente en cáncer de mama
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
RU2330067C2 (ru) 2001-12-19 2008-07-27 Дзе Юниверсити Оф Чикаго Полинуклеотид, кодирующий хромо- или флуоресцирующий мутантный полипептид, вектор экспрессии, клетка, способ получения хромо- или флуоресцирующего полипептида, набор для получения хромо- или флуоресцирующего полипептида, применение полипептида и применение полинуклеотида
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EP1572720A4 (de) 2002-05-24 2008-12-24 Nps Allelix Corp Verfahren zur enzymatischen herstellung von glp-2-(1-33)- und glp-2-(1-34)-peptiden
AU2003239865A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Method for universal enzymatic production of bioactive peptides
AU2003255406B2 (en) 2002-09-11 2009-09-10 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DK1842920T4 (da) 2003-09-23 2017-08-21 Univ North Carolina Chapel Hill Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
PT1673450E (pt) 2003-10-14 2010-05-11 Baxter Int Polipéptido de reciclagem de epóxido de vitamina k, vkorc1, um alvo terapêutico de cumarina e seus derivados
CA2546319A1 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
SG151261A1 (en) 2004-03-11 2009-04-30 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2005092391A2 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
EP1732944B1 (de) 2004-04-07 2012-09-05 The University of Chicago Monomere, rotfluoreszierende proteine
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
CA2602175C (en) 2005-03-21 2012-11-27 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
CA2613257A1 (en) 2005-06-24 2006-12-28 Teijin Pharma Limited A novel biological substance nesfatin and its related substances and uses thereof
EP1762250A1 (de) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP2339014B1 (de) 2005-11-16 2015-05-27 Ambrx, Inc. Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
DE102006058373A1 (de) 2006-12-08 2008-06-12 Evocatal Gmbh (R)-Hydroxynitril-Lyase aus Brassicaceen
DE102007014742A1 (de) 2007-03-23 2008-09-25 Evonik Degussa Gmbh Isoformen der Schweineleber Esterase
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
EP3241846B1 (de) 2007-10-04 2022-02-23 ZymoGenetics, Inc. B7-familienmitglied zb7h6 sowie zugehörige zusammensetzungen und verfahren
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
EP2342223B1 (de) 2008-09-26 2017-04-26 Ambrx, Inc. Modifizierte tiererythropoietinpolypeptide und anwendungen davon
DE102009007272A1 (de) 2009-02-03 2010-08-05 Evocatal Gmbh Alkoholdehydrogenase aus Gluconobacter oxydans und deren Verwendung
EP2292781A1 (de) 2009-08-17 2011-03-09 Genethon Baculovirus-basierte Herstellung von Biopharmazeutika ohne kontaminierende baculovirale Virionen
EP2333074A1 (de) 2009-12-14 2011-06-15 Robert Steinfeld Substanzen und Verfahren zur Behandlung von lyosomalen Speicherkrankheiten
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
EP2599004A4 (de) * 2010-07-26 2013-12-11 Seven Networks Inc Vorhersage einer aktivitätssitzung zur optimierung der verwendung eins mobilnetzwerks und zur verstärkung eines benutzererlebnisses
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
BR112014001863A2 (pt) 2011-07-27 2017-02-21 Genethon sistemas de expressão baculovírus melhorados
CA3178379A1 (en) 2013-09-12 2015-03-19 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
MX2018003702A (es) 2015-09-24 2018-04-30 Biomarin Pharm Inc Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden.
IL259178B (en) 2015-11-12 2022-08-01 Res Inst Nationwide Childrens Hospital A vector encoding ano5 for the treatment of muscular dystrophy
HK1257955A1 (zh) 2015-11-16 2019-11-01 The Research Institute At Nationwide Children's Hospital 用於治疗肌联蛋白类肌病和其他肌联蛋白病变的材料和方法
EP3222712A1 (de) 2016-03-22 2017-09-27 Universität zu Köln Alkoholdehydrogenase aus pichia pastoris und ihre verwendung
EP3491008A2 (de) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Neuartige adeno-assoziierte virus-kapsid-proteine
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200231986A1 (en) 2017-09-29 2020-07-23 Massachusetts Eye And Ear Infirmary Production of adeno-associated viruses in insect cells
KR102824021B1 (ko) 2018-01-31 2025-06-24 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 2c형 지대근이영양증에 대한 유전자 치료
EP3790627A2 (de) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Verfahren zur behandlung von phenylketonurie
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるａａｖベクターの安定的発現
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
MX2020014119A (es) 2018-06-29 2021-06-18 Res Inst Nationwide Childrens Hospital Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
MX2021010356A (es) 2019-02-26 2022-03-04 Res Inst Nationwide Childrens Hospital SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
CN120400170A (zh) 2019-08-21 2025-08-01 全国儿童医院研究所 Α-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
WO2021062164A1 (en) 2019-09-27 2021-04-01 Biomarin Pharmaceutical Inc. Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
AU2020384294A1 (en) 2019-11-14 2022-06-02 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
EP4103699A1 (de) 2020-02-10 2022-12-21 BioMarin Pharmaceutical Inc. Virusfreie zellkulturen
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
JP7733110B2 (ja) 2020-11-02 2025-09-02 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルスを濃縮するためのプロセス
US20240408240A1 (en) 2021-10-01 2024-12-12 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
EP4219726A1 (de) 2021-10-15 2023-08-02 Research Institute at Nationwide Children's Hospital Selbstkomplementärer adeno-assoziierter virusvektor und dessen verwendung bei der behandlung von muskeldystrophie
CA3267804A1 (en) 2022-09-22 2024-03-28 Dinaqor Ag TREATMENT OF CARDIOMYOPATHY USING AAV GENE THERAPY VECTORS
UY40442A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
TW202444398A (zh) 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Also Published As

Publication number Publication date
AU581174B2 (en) 1989-02-16
JPS6037988A (ja) 1985-02-27
BR8402666A (pt) 1985-05-07
NO173944B (no) 1993-11-15
NO173944C (no) 1994-02-23
EP0127839B1 (de) 1992-07-15
DK172401B1 (da) 1998-05-18
DE3485810T2 (de) 1992-12-10
JPH0779700B2 (ja) 1995-08-30
MX164250B (es) 1992-07-27
ATE78293T1 (de) 1992-08-15
ES532825A0 (es) 1985-08-16
NZ208259A (en) 1988-01-08
EP0127839A2 (de) 1984-12-12
JP2644447B2 (ja) 1997-08-25
IL71906A0 (en) 1984-09-30
AU2871784A (en) 1984-11-29
DK257984A (da) 1984-11-28
IE58011B1 (en) 1993-06-16
KR840008818A (ko) 1984-12-19
IE841269L (en) 1984-11-27
JPH0799989A (ja) 1995-04-18
IN160416B (de) 1987-07-11
CA1222213A (en) 1987-05-26
KR910009203B1 (ko) 1991-11-04
DK257984D0 (da) 1984-05-25
ES8507176A1 (es) 1985-08-16
DE3485810D1 (de) 1992-08-20
NO842094L (no) 1984-11-28
PH25395A (en) 1991-06-03
EP0127839A3 (en) 1986-06-25

Similar Documents

Publication Publication Date Title
IL71906A (en) Method for producing a baculovirus vector capable of producing a selected non-fused recombinant protein or capable of being utilized as a transfer vector;a recombinant baculovirus expression vector capable of expressing under the control of a baculovirus polyhedrin promoter a selected non-fused protein in a host insect cell;a recombinant transfer vector utilizing a baculovirus polyhedrin promoter and flanking sequences for introducing a selected gene into a baculovirus genome,or for insertion of a selected gene for a genetic manipulation of a baculovirus;and a method for the synthesis of a selected non-fused protein in a host insect cell using the expression vector
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
KR830003574A (ko) 변칙합성 유전자의 미생물을 통한 발현
CA2703161A1 (en) Plant-optimized polynucleotides encoding approximately 15 kda and approximately 45 kda pesticidal proteins
Bex et al. Mini‐F encoded proteins: identification of a new 10.5 kilodalton species.
EP0111814A3 (de) Klonierung und Expression von nucleotiden Sequenzen die für Rinderwachstumshormon kodieren
DE3278539D1 (en) T4 dna fragment as a stabilizer for proteins expressed by cloned dna
EP0837931A4 (de) Methode zur expression in und isolation von biologisch aktiven molekülen aus urin
AU2745992A (en) Biosynthetic process for the preparation of chemical compounds
KR930702528A (ko) 스트렙토마이세스 리비단으로부터 분리하고 정제한 단백질 가수분해 효소 x를 암호화하는 dna 시퀸스
AU5392279A (en) Stable high copy number plasmids
RU2001104431A (ru) Способ получения белков в трансформированных дрожжевых клетках
ATE122097T1 (de) Expressionsvektor und verfahren zur regulierbaren herstellung von proteinen in eukaryonten.
KR970001543A (ko) 신규 프로모터 및 이를 이용한 유전자 발현 방법
TW287199B (en) A method for genetically producing a protein exhibiting the activity of epstein-barr virus DNA polymerase

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired